Related Experiment Video

Updated: Sep 30, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Chronic hepatitis B: current and future treatment options

Anastasia Rivkina1, Sergey Rybalov

  • 1Arnold and Marie Schwartz College of Pharmacy, Long Island University, Brooklyn, New York, USA. arivkina@liu.edu

Pharmacotherapy
|June 18, 2002
PubMed

Insights

Hepatitis B is a serious global health threat. Effective management and prevention strategies, including new drug development, are crucial for controlling this viral infection and its severe complications like liver cancer.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis B virus (HBV) infection is a significant global health concern, ranking as the ninth leading cause of mortality worldwide.
  • HBV infection can progress to severe liver diseases, including cirrhosis and hepatocellular carcinoma, underscoring the need for effective prevention and treatment strategies.

Observation:

  • Current Food and Drug Administration-approved pharmacotherapeutic agents for chronic hepatitis B include interferon-alpha-2b and lamivudine.
  • Emerging therapeutic agents show promise for improved management, with ongoing research into drugs such as adefovir, entecavir, and emtricitabine.
  • Novel treatment modalities, including therapeutic vaccines and immunomodulators like thymosin alpha-1, are under development.

Findings:

  • The landscape of hepatitis B pharmacotherapy is expanding with numerous new agents demonstrating potential efficacy.
  • Treatment strategies for hepatitis B infection in liver transplant recipients are also advancing, incorporating agents like hepatitis B immunoglobulin and nucleoside analogues.

Implications:

  • Advancements in antiviral therapies and preventative measures are critical for reducing the global burden of hepatitis B and its sequelae.
  • Further research and clinical trials are essential to fully evaluate the safety and efficacy of novel hepatitis B treatments.

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...